$67.92
1.87%
Nasdaq, Apr 21, 08:15 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$69.21
+4.86 7.55% 1M
+9.09 15.12% 6M
+13.93 25.20% YTD
+3.73 5.70% 1Y
+38.01 121.83% 3Y
+26.08 60.47% 5Y
+1.67 2.47% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.01 0.01%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Market capitalization $1.49b
Enterprise Value $2.00b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 41.82
EV/Sales (TTM) EV/Sales 3.25
P/S ratio (TTM) P/S ratio 2.43
P/B ratio (TTM) P/B ratio 3.62
Revenue growth (TTM) Revenue growth 26.20%
Revenue (TTM) Revenue $614.38m
EBIT (operating result TTM) EBIT $2.22m
Free Cash Flow (TTM) Free Cash Flow $47.78m
Cash position $151.20m
EPS (TTM) EPS $-1.13
P/E forward 69.38
P/S forward 1.94
EV/Sales forward 2.60
Short interest 15.55%
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
13%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
614 614
26% 26%
100%
- Direct Costs 318 318
32% 32%
52%
296 296
21% 21%
48%
- Selling and Administrative Expenses 182 182
80% 80%
30%
- Research and Development Expense 45 45
30% 30%
7%
70 70
37% 37%
11%
- Depreciation and Amortization 68 68
12% 12%
11%
EBIT (Operating Income) EBIT 2.22 2.22
96% 96%
0%
Net Profit -20 -20
208% 208%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open.
Neutral
GlobeNewsWire
21 days ago
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows:
Neutral
GlobeNewsWire
about one month ago
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI's Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®.
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today